Evidence map›Paper›PMID 35748739›Full record

ArticleCancer research2022

Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer.

Viswam S Nair, Angela Bik-Yu Hui, Jacob J Chabon, Mohammad S Esfahani, Henning Stehr, Barzin Y Nabet, Li Zhou, Aadel A Chaudhuri, Jalen Benson, Kelsey Ayers and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Bronchoalveolar lavage fluidTranslational lung cancer research · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. [Application of puncture tissue rinse solution in the detection ofZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  9. Article
  10. Article
  11. Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  12. Article
  13. Review
  14. Advances in laboratory medicine · 2025
    Article
  15. Review
  16. Advances in laboratory medicine · 2025
    Article
  17. Integrating ctDNA testing forAdvances in laboratory medicine · 2025
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 2 countries.

Viswam S Nair *Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0001-6376-8154
Angela Bik-Yu Hui *Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Jacob J ChabonStanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-1820-9737
Mohammad S EsfahaniStanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Henning StehrDepartment of Pathology, Stanford University School of Medicine, Stanford, California.
Barzin Y NabetStanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-4824-3533
Li ZhouStanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-7099-0711
Aadel A ChaudhuriDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-3115-3061
Jalen BensonDivision of Thoracic Surgery, Stanford University School of Medicine, Stanford, California.
Kelsey AyersDivision of Thoracic Surgery, Stanford University School of Medicine, Stanford, California.
Harmeet BediDivision of Pulmonary, Allergy & Critical Care Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-7241-4881
Meghan RamseyDivision of Pulmonary, Allergy & Critical Care Medicine, Stanford University School of Medicine, Stanford, California.
Ryan Van WertDivision of Pulmonary, Allergy & Critical Care Medicine, Stanford University School of Medicine, Stanford, California.
Sanja AnticDivision of Allergy, Pulmonary & Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Natalie LuiDivision of Thoracic Surgery, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-6602-6372
Leah BackhusDivision of Thoracic Surgery, Stanford University School of Medicine, Stanford, California.
Mark BerryDivision of Thoracic Surgery, Stanford University School of Medicine, Stanford, California.
Arthur W SungDivision of Pulmonary, Allergy & Critical Care Medicine, Stanford University School of Medicine, Stanford, California.
Pierre P Massion *Division of Allergy, Pulmonary & Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Joseph B ShragerDivision of Thoracic Surgery, Stanford University School of Medicine, Stanford, California.
Ash A AlizadehStanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-5153-5625
Maximilian DiehnStanford Cancer Institute, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-2032-0581
Stanford University · USCalifornia Institute for Regenerative Medicine · USStanford Medicine · USVanderbilt University · USUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkersP50CA228944 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI A McGarry Houghton · 2019 to 2026
$19.6M
Molecularly-based outcome and toxicity prediction after radiotherapy for lung cancerR01CA254179 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.1M
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerR01CA244526 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.0M
Developing a genomic approach for cancer screeningDP2CA186569 · NCI · STANFORD UNIVERSITY · PI DIEHN, MAXIMILIAN · 2013 to 2013
$2.4M
Liquid biopsy of the lung to profile lung cancerU01CA253166 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HOUGHTON, A MCGARRY, NAIR, VISWAM SIVA · 2020 to 2024
$2.0M
Noninvasive monitoring of lung cancer patients treated with radiotherapyR01CA188298 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2015 to 2019
$1.8M
High-throughput sequencer for multi-scale genomic studiesS10OD020141 · OD · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2015 to 2015
$600k
NCI NIH HHS DP2 CA186569NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA228944NCI NIH HHS R01 CA188298NCI NIH HHS R01 CA244526NCI NIH HHS R01 CA254179NCI NIH HHS U01 CA253166NIH HHS S10 OD020141
6 · The paper itself

Abstract

Genomic profiling of bronchoalveolar lavage (BAL) samples may be useful for tumor profiling and diagnosis in the clinic. Here, we compared tumor-derived mutations detected in BAL samples from subjects with non-small cell lung cancer (NSCLC) to those detected in matched plasma samples. Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) was used to genotype DNA purified from BAL, plasma, and tumor samples from patients with NSCLC. The characteristics of cell-free DNA (cfDNA) isolated from BAL fluid were first characterized to optimize the technical approach. Somatic mutations identified in tumor were then compared with those identified in BAL and plasma, and the potential of BAL cfDNA analysis to distinguish lung cancer patients from risk-matched controls was explored. In total, 200 biofluid and tumor samples from 38 cases and 21 controls undergoing BAL for lung cancer evaluation were profiled. More tumor variants were identified in BAL cfDNA than plasma cfDNA in all stages (P < 0.001) and in stage I to II disease only. Four of 21 controls harbored low levels of cancer-associated driver mutations in BAL cfDNA [mean variant allele frequency (VAF) = 0.5%], suggesting the presence of somatic mutations in nonmalignant airway cells. Finally, using a Random Forest model with leave-one-out cross-validation, an exploratory BAL genomic classifier identified lung cancer with 69% sensitivity and 100% specificity in this cohort and detected more cancers than BAL cytology. Detecting tumor-derived mutations by targeted sequencing of BAL cfDNA is technically feasible and appears to be more sensitive than plasma profiling. Further studies are required to define optimal diagnostic applications and clinical utility. SIGNIFICANCE: Hybrid-capture, targeted deep sequencing of lung cancer mutational burden in cell-free BAL fluid identifies more tumor-derived mutations with increased allele frequencies compared with plasma cell-free DNA. See related commentary by Rolfo et al., p. 2826.

Indexed as

Carcinoma, Non-Small-Cell LungCell-Free Nucleic AcidsLung NeoplasmsBiomarkers, TumorBronchoalveolar Lavage FluidDNA, NeoplasmGenomicsHigh-Throughput Nucleotide SequencingHumansMutationBiomarkers, TumorCell-Free Nucleic AcidsDNA, Neoplasm

Identifiers

PMID35748739
PMCPMC9379362
OpenAlexW4283457534

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.